"Surveyed nephrologists forecast a significant increase in Omontys patient share in the next six months. For hemodialysis and peritoneal dialysis (PD) patients in particular; Omontys growth is expected at the expense of Amgen's Epogen. In keeping with the approved indication, fewer nephrologists expect to use Omontys in the CKD-non-dialysis (CKD-ND) patient population";
"In this second wave of research, we found a changing dynamic in the way surveyed nephrologists perceive the potential patient types for Omontys. Awareness of the indication has directionally increased, and as such, Omontys is likely to be used as indicated—in the dialysis patient population—anticipated use of the drug in CKD-ND patients has significantly declined since wave 1," said BioTrends' Associate Therapeutic Class Director-Nephrology Rob Dubman. "However, there is a high opportunity for Omontys to increase patient share as evidenced by the fact that surveyed nephrologists believe that over half of their hemodialysis ESA-treated patients are likely Omontys candidates."